Search Results - "Jones, Rob J"

Immune checkpoint inhibitors in renal cell carcinoma by Ross, Kirsty, Jones, Rob J

“…The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for…”
Get more information

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer by Hoyle, Alex P., Ali, Adnan, James, Nicholas D., Cook, Adrian, Parker, Christopher C., de Bono, Johann S., Attard, Gerhardt, Chowdhury, Simon, Cross, William R., Dearnaley, David P., Brawley, Christopher D., Gilson, Clare, Ingleby, Fiona, Gillessen, Silke, Aebersold, Daniel M., Jones, Rob J., Matheson, David, Millman, Robin, Mason, Malcolm D., Ritchie, Alastair W.S., Russell, Martin, Douis, Hassan, Parmar, Mahesh K.B., Sydes, Matthew R., Clarke, Noel W.

“…Abiraterone acetate received licencing for use in only “high-risk” metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings…”
Get full text

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data by Clarke, Caroline S, Hunter, Rachael M, Gabrio, Andrea, Brawley, Christopher D, Ingleby, Fiona C, Dearnaley, David P, Matheson, David, Attard, Gerhardt, Rush, Hannah L, Jones, Rob J, Cross, William, Parker, Chris, Russell, J Martin, Millman, Robin, Gillessen, Silke, Malik, Zafar, Lester, Jason F, Wylie, James, Clarke, Noel W, Parmar, Mahesh K B, Sydes, Matthew R, James, Nicholas D

“…Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients…”
Get full text

Evidencing the impact of cancer trials: insights from the 2014 UK Research Excellence Framework by Hanna, Catherine R, Gatting, Lauren P, Boyd, Kathleen Anne, Robb, Kathryn A, Jones, Rob J

“…An impactful clinical trial will have real-life benefits for patients and society beyond the academic environment. This study analyses case studies of cancer…”
Get full text

The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis by Elyan, Benjamin M P, Sullivan, Michael K, Hedley, James, De La Mata, Nicole, Webster, Angela C, Venugopal, Balaji, Jones, Rob J, Lang, Ninian N, Mark, Patrick B, Lees, Jennifer S

“…Drugs targeting angiogenesis and immunotherapy have transformed outcomes in renal cancer but may contribute to progressive kidney disease.BACKGROUNDDrugs…”
Get full text

Circulating biomarkers in cancer care: What possible use? by Jones, Rob J., Brown, Jennifer

“…The practice of the physician has changed greatly in the last 100 years. Yet, the fundamental role remains constant: it is the physician's function to make a…”
Get full text

Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer by Boyd, Kathleen A, Jones, Rob J, Paul, Jim, Birrell, Fiona, Briggs, Andrew H, Leung, Hing Y

“…ObjectiveTo determine the cost-effectiveness of salvage cryotherapy (SC) in men with radiation recurrent prostate cancer (RRPC).DesignCost-utility analysis…”
Get full text

Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real‐world findings from NHS England between 2013 and 2019 by Catto, James W.F., Mandrik, Olena, Quayle, Lewis A., Hussain, Syed A., McGrath, John, Cresswell, Joanne, Birtle, Alison J., Jones, Rob J., Mariappan, Paramananthan, Makaroff, Lydia E., Knight, Allen, Mostafid, Hugh, Chilcott, Jim, Sasieni, Peter, Cumberbatch, Marcus

“…Objective We report NHS England data for patients with bladder cancer (BC), upper tract urothelial cancer (UTUC: renal pelvic and ureteric), and urethral…”
Get full text

Diagnosis, treatment, and survival from kidney cancer: real‐world National Health Service England data between 2013 and 2019 by Conroy, Samantha, Catto, James W.F., Bex, Axel, Brown, Janet E., Cartledge, Jon, Fielding, Alison, Jones, Rob J., Khoo, Vincent, Nicol, David, Stewart, Grant D., Sullivan, Mark, Tran, Maxine G.B., Woodward, Rose, Cumberbatch, Marcus G.

“…Objectives To report the NHS Digital (NHSD) data for patients diagnosed with kidney cancer (KC) in England. We explore the incidence, route to diagnosis (RTD),…”
Get full text

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial by Mason, Malcolm D, Clarke, Noel W, James, Nicholas D, Dearnaley, David P, Spears, Melissa R, Ritchie, Alastair W S, Attard, Gerhardt, Cross, William, Jones, Rob J, Parker, Christopher C, Russell, J Martin, Thalmann, George N, Schiavone, Francesca, Cassoly, Estelle, Matheson, David, Millman, Robin, Rentsch, Cyrill A, Barber, Jim, Gilson, Clare, Ibrahim, Azman, Logue, John, Lydon, Anna, Nikapota, Ashok D, O'Sullivan, Joe M, Porfiri, Emilio, Protheroe, Andrew, Srihari, Narayanan Nair, Tsang, David, Wagstaff, John, Wallace, Jan, Walmsley, Catherine, Parmar, Mahesh K B, Sydes, Matthew R

“…Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage,…”
Get full text

The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers by Jones, Rob J., Boyce, Tamsin, Fennell, Michael, Jacobs, Vivien, Pinto, Francesco, Duffield, Emma, Clack, Glen, Green, Tim, Kelly, John, Robertson, John

“…Demonstration of pharmacodynamic activity of new, targeted cancer drugs in tumour tissue is potentially important in guiding early drug development. However,…”
Get full text

Final quality of life and safety data for patients with metastatic castration‐resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279) by Bahl, Amit, Masson, Susan, Malik, Zafar, Birtle, Alison J., Sundar, Santhanam, Jones, Rob J., James, Nicholas D., Mason, Malcolm D., Kumar, Satish, Bottomley, David, Lydon, Anna, Chowdhury, Simon, Wylie, James, Bono, Johann S.

“…Objective To compile the safety profile and quality of life (QoL) data for patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with…”
Get full text

Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer by Molife, L Rhoda, Omlin, Aurelius, Jones, Rob J, Karavasilis, Vasilios, Bloomfield, David, Lumsden, Graeme, Fong, Peter C, Olmos, David, O'Sullivan, Joe M, Pedley, Ian, Hickish, Tamas, Jenkins, Peter, Thompson, Emilda, Oommen, Nikhil, Wheatley, Duncan, Heath, Catherine, Temple, Graham, Pelling, Katy, de Bono, Johann S

“…The aim of this article was to evaluate afatinib (BIBW 2992), an ErbB family blocker, and nintedanib (BIBF 1120), a triple angiokinase inhibitor, in…”
Get more information

Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma by Venugopal, Balaji, Ansari, Jawaher, Aitchison, Michael, Tho, Lye Mun, Campbell, Roderick, Jones, Rob J

“…Renal cell carcinoma (RCC) is a histopathologically and molecularly heterogeneous disease with the chromophobe subtype (chRCC) accounting for approximately 5%…”
Get full text

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness by Woods, Beth S., Sideris, Eleftherios, Sydes, Matthew R., Gannon, Melissa R., Parmar, Mahesh K.B., Alzouebi, Mymoona, Attard, Gerhardt, Birtle, Alison J., Brock, Susannah, Cathomas, Richard, Chakraborti, Prabir R., Cook, Audrey, Cross, William R., Dearnaley, David P., Gale, Joanna, Gibbs, Stephanie, Graham, John D., Hughes, Robert, Jones, Rob J., Laing, Robert, Mason, Malcolm D., Matheson, David, McLaren, Duncan B., Millman, Robin, O'Sullivan, Joe M., Parikh, Omi, Parker, Christopher C., Peedell, Clive, Protheroe, Andrew, Ritchie, Alastair W.S., Robinson, Angus, Russell, J. Martin, Simms, Matthew S., Srihari, Narayanan N., Srinivasan, Rajaguru, Staffurth, John N., Sundar, Santhanam, Thalmann, George N., Tolan, Shaun, Tran, Anna T.H., Tsang, David, Wagstaff, John, James, Nicholas D., Sculpher, Mark J.

“…Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate…”
Get full text

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial by Parker, Chris C, James, Nicholas D, Brawley, Christopher D, Clarke, Noel W, Ali, Adnan, Amos, Claire L, Attard, Gerhardt, Chowdhury, Simon, Cook, Adrian, Cross, William, Dearnaley, David P, Douis, Hassan, Gilbert, Duncan C, Gilson, Clare, Gillessen, Silke, Hoyle, Alex, Jones, Rob J, Langley, Ruth E, Malik, Zafar I, Mason, Malcolm D, Matheson, David, Millman, Robin, Rauchenberger, Mary, Rush, Hannah, Russell, J Martin, Sweeney, Hannah, Bahl, Amit, Birtle, Alison, Capaldi, Lisa, Din, Omar, Ford, Daniel, Gale, Joanna, Henry, Ann, Hoskin, Peter, Kagzi, Mohammed, Lydon, Anna, O'Sullivan, Joe M, Paisey, Sangeeta A, Parikh, Omi, Pudney, Delia, Ramani, Vijay, Robson, Peter, Srihari, Narayanan Nair, Tanguay, Jacob, Parmar, Mahesh K B, Sydes, Matthew R

“…STAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed prostate cancer with…”
Get full text

Abstract CT027: Safety, pharmacokinetics (PK) & pharmacodynamics (PD) of idasanutlin (idasa), combined with abiraterone (abi)/prednisolone (pred) or enzalutamide (enza) in castrate resistant prostate cancer (CRPC) by Roxburgh, Patricia, Currie, Dawn, Morrison, Paula, Kelly, Caroline, Thomson, Fiona, McCormick, Carol, Bilsland, Alan, Jones, Robert H., Quinton, Amy, McCartney, Elaine, Barwell, Lorraine, Jones, Rob J.

“…Abstract Introduction MDM2 inhibitor idasa aims to treat cancers retaining functional TP53, inactivated by binding of negative regulator, MDM2. Many CRPCs…”
Get full text

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial by Chris C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Adnan Ali, Claire L Amos, Gerhardt Attard, Simon Chowdhury, Adrian Cook, William Cross, David P Dearnaley, Hassan Douis, Duncan C Gilbert, Clare Gilson, Silke Gillessen, Alex Hoyle, Rob J Jones, Ruth E Langley, Zafar I Malik, Malcolm D Mason, David Matheson, Robin Millman, Mary Rauchenberger, Hannah Rush, J Martin Russell, Hannah Sweeney, Amit Bahl, Alison Birtle, Lisa Capaldi, Omar Din, Daniel Ford, Joanna Gale, Ann Henry, Peter Hoskin, Mohammed Kagzi, Anna Lydon, Joe M O'Sullivan, Sangeeta A Paisey, Omi Parikh, Delia Pudney, Vijay Ramani, Peter Robson, Narayanan Nair Srihari, Jacob Tanguay, Mahesh K B Parmar, Matthew R Sydes, STAMPEDE Trial Collaborative Group

“…BackgroundSTAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed prostate…”
Get full text

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data by Caroline S Clarke, Rachael M Hunter, Andrea Gabrio, Christopher D Brawley, Fiona C Ingleby, David P Dearnaley, David Matheson, Gerhardt Attard, Hannah L Rush, Rob J Jones, William Cross, Chris Parker, J Martin Russell, Robin Millman, Silke Gillessen, Zafar Malik, Jason F Lester, James Wylie, Noel W Clarke, Mahesh K B Parmar, Matthew R Sydes, Nicholas D James

“…Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients…”
Get full text

Clinical Development of Src Family Kinase Inhibitors in Malignant Melanoma by Macpherson, Iain R.J., Jones, Rob J., Evans, T.R. Jeffry

Get full text